CSL Limited (CSLLY) Stock Price & Analysis
CSL Limited (CSLLY) — price $30.75 (+0.70%), as of the Oct 5, 2026 trading session; market cap $118B.
Educational signal · not a buy or sell recommendation · How to read this
CSL Limited · CSLLY · Healthcare · Biotechnology
Research dated 2026-09-12: CSL is a scaled biopharmaceutical manufacturer whose sales come from plasma-derived and recombinant therapies, influenza-focused products, and related licensing income. Its defining financial question is whether a business that still produces substantial operating cash can restore the connection between revenue growth and net profit after a sharp earnings reversal.
Price as of Oct 5, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $30.75 | |
| Change on the day | +0.70% | |
| 52-week range | $16.01 – $36.28 | |
| Market capitalisation | $118B | |
| Price / earnings (trailing) | 24.09 | |
| Shares traded on the day | 404 | |
| Beta (volatility vs the S&P 500) | 0.08 | |
| Dividends per share (last 12 months) | $0.72 | |
| Dividend yield (last 12 months) | 2.37% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results
- · Earnings results
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Other perspectives
Council score for CSL (CSLLY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the CSLLY film — every key number, told as a short cinematic story
~2 min · open the film
What is CSL (CSLLY), and what does it report?
Short answer · as of
CSL Behring supplies plasma-derived and recombinant therapies for immunodeficiency, bleeding disorders, hereditary angioedema, respiratory deficiency, and neurological conditions, while Seqirus develops and supplies non-plasma biotherapeutics focused on influenza.
Research dated 2026-09-12.
CSL Behring supplies plasma-derived and recombinant therapies for immunodeficiency, bleeding disorders, hereditary angioedema, respiratory deficiency, and neurological conditions, while Seqirus develops and supplies non-plasma biotherapeutics focused on influenza. Licensing and royalties supplement product revenue.
Reported revenue therefore combines treatment demand across serious chronic conditions, influenza-related product demand, and intellectual-property income. CSL is better understood as a global specialty-biologics producer than as a biotechnology company whose economics depend mainly on research milestones.
What do the latest results show for CSL (CSLLY)?
Short answer · as of
The most recent reported quarter, Q4 FY2026, carried revenue of $7.44B.
Research dated 2026-09-12.
Annual revenue continued to rise, but the company moved from substantial net profit to a substantial net loss. In the latest reported period, revenue declined from the preceding period, gross profit contracted, operating profit weakened, and the net result turned sharply negative.
The important change is the collapse in conversion from sales and operating profit into bottom-line earnings, rather than a disappearance of revenue. Operating cash flow remained positive and increased from the preceding period, so the earnings reversal did not produce a matching collapse in cash generated by the business.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $7.44B Jun 30, 2026
- Latest quarter · R&D
- $625.09M Jun 30, 2026
- Latest quarter · SG&A
- $1.12B Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $1.41B Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $7.44B | $625.09M | $1.12B | $1.41B |
| Dec 31, 2025 | $8.30B | $601.04M | $1.01B | $2.60B |
| Jun 30, 2025 | $7.26B | $739.08M | $1.22B | $1.40B |
| Dec 31, 2024 | $8.21B | $646.00M | $1.18B | $2.76B |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $7.44B Aug 17, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 17, 2026 | $7.44B | Not available | −$1.5600 | Not available |
| Feb 10, 2026 | $8.30B | Not available | $0.0550 | Not available |
| Feb 10, 2025 | $8.21B | Not available | $0.2594 | Not available |
| Aug 13, 2024 | $6.75B | Not available | $0.1456 | Not available |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2026 | $7.44B | -$2.99B | -$1.56 (diluted) |
| Q2 FY2026 | $8.30B | $402M | $0.05 (diluted) |
| Q4 FY2025 | $7.26B | $1.03B | — |
| Q2 FY2025 | $8.21B | $2.01B | $0.26 (diluted) |
What are the financial strengths and risks for CSL (CSLLY)?
Short answer
Cash and short-term investments were $1.51B at the Jun 30, 2026 balance-sheet date. Operating cash flow was $2.22B for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
CSL continues to generate substantial operating cash after capital expenditure, and cash has remained broadly stable across the reported window despite fluctuations between periods. Short-term liquidity appears adequate, while the quality and distress screens remain favorable.
Debt nevertheless stands far above cash and investments, leaving the balance sheet in a net-debt position. The company-specific risk is prolonged divergence between positive operating profit and negative net income: continued charges below the operating line could weaken retained financial capacity even while the core businesses remain cash generative.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $2.22B Jun 30, 2026
- Previous quarter · operating cash flow
- $1.30B Dec 31, 2025
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $2.22B | −$351.65M |
| Dec 31, 2025 | $1.30B | −$296.51M |
| Jun 30, 2025 | $2.44B | −$283.23M |
| Dec 31, 2024 | $1.26B | −$378.00M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at CSL (CSLLY)?
Research dated 2026-09-12.
Watch whether net income reconnects with operating profit, whether gross profit stabilizes as revenue changes, and whether operating cash flow continues to cover capital expenditure. Cash should also be read against debt rather than in isolation, because recent cash stability does not remove the net-debt exposure.
Research spending deserves attention alongside the earnings recovery: CSL must support plasma, recombinant, and influenza programs while protecting cash generation. Published estimates imply restrained revenue progression and only modest later earnings improvement, making the direction of actual profit conversion more informative than revenue growth alone.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How is CSL scored?
Research dated 2026-09-12.
CSL differs from a development-stage biotechnology company because it already manufactures and distributes commercial therapies at global scale, produces operating cash, and earns some licensing and royalty income. It also differs from a narrowly focused drugmaker because plasma-derived and recombinant therapies sit alongside an influenza-focused non-plasma operation.
That structure spreads demand across rare and serious conditions and influenza products, but it also makes consolidated revenue an imperfect guide to underlying economics. Product mix, gross-profit conversion, research spending, and the gap between operating and net income matter more than pipeline headlines alone.
| Company | Price | Market value | Score |
|---|---|---|---|
| $936.00 Oct 2, 2026 | $58.2B | — Model unavailable | |
| $39.19 Oct 5, 2026 | $64.5B | — Model unavailable | |
| $22.77 Oct 2, 2026 | $91.2B | — Model unavailable | |
| $351.17 Oct 5, 2026 | $21.6B | — Model unavailable | |
| $37.32 Oct 2, 2026 | $166B | — 5-pillar · not comparable | |
| $504.73 Oct 2, 2026 | $128B | — 5-pillar · not comparable | |
| $735.20 Oct 2, 2026 | $75.7B | — 5-pillar · not comparable | |
| $219.72 Oct 2, 2026 | $29.4B | — 5-pillar · not comparable | |
| $57.16 Oct 2, 2026 | $25.3B | — 5-pillar · not comparable | |
| $113.81 Oct 5, 2026 | $23.1B | — 5-pillar · not comparable | |
| $541.70 Oct 2, 2026 | $23.0B | — 5-pillar · not comparable | |
| $58.84 Oct 5, 2026 | $14.8B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 0.0% Period end Jun 30, 2026
- Previous quarter · ownership
- 0.0% Prior to period end Jun 30, 2026
- Reporting holders
- 6 Period end Jun 30, 2026
- Previous quarter · holders
- 7 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Rhumbline Advisers | 23,969 |
| Gamma Investing LLC | 3,694 |
| Salomon & Ludwin, LLC | 1,993 |
| Pnc Financial Services Group, INC. | 220 |
| Ima Wealth, INC. | 29 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about CSL (CSLLY)?
What Investors Ask About CSL (CSLLY) — Healthcare
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do CSL Behring and Seqirus differ?
CSL Behring concentrates on plasma-derived and recombinant therapies for serious medical conditions, while Seqirus focuses on non-plasma biotherapeutics related to influenza. Their revenue drivers therefore reflect different treatment categories within the same consolidated company.
What does CSL’s gap between operating profit and net loss mean?
The latest statements show that the business remained profitable at the operating line while the final result was deeply negative. Bottom-line earnings therefore deteriorated far more severely than revenue or operating activity.
Does CSL’s plasma therapy business still produce cash after the reported loss?
Consolidated operating cash flow remained substantial and exceeded capital expenditure despite the reported net loss. That cash performance separates the latest accounting loss from the cash generated by CSL’s operations, although the available figures do not isolate plasma therapies from Seqirus.
Why does CSL’s cash balance matter against its debt load?
Cash and investments provide liquidity, but they cover only a minority of total debt. CSL therefore depends more on continued operating cash generation than on its cash reserve alone when meeting financial obligations and funding investment.
What is the CSLLY stock price today?
The last price recorded on this page for CSL Limited (CSLLY) is $30.75, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does CSLLY pay a dividend?
Yes. CSL Limited (CSLLY) shows a trailing 12-month dividend yield of 2.37%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (60 figures)
The 60 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 45 Poplar RD, Prakville Victoria Austra, C3, 00000 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "655 Elizabeth Street, Melbourne, VIC, 3000, AU". |
FMP — 56 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $30.75 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T14:55:02.741Z. | |
px.change | Change on the day | +0.70% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalization | $118B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-02. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$0.215 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 24.09 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 404 | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.08 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Gordon Naylor DipCompSc | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 29,000 | FMP | Financial Modeling Prep (FMP) company profile | |
fin.q_revenue | Revenue, Q4 FY2026 | $7.44B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2022 through FY2026: FY2022 revenue $10.49B, net result $2.25B; FY2023 revenue $13.17B, net result $2.19B; FY2024 revenue $14.80B, net result $2.64B; FY2025 revenue $15.43B, net result $3.00B; FY2026 revenue $15.77B, net result −$2.59B | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 47.8% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $7.44B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $625.09M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $1.12B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $1.41B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $8.30B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $601.04M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $1.01B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $2.60B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.revenue_k | Revenue — period end 2025-06-30 | $7.26B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.rd_k | R&D — period end 2025-06-30 | $739.08M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.sga_k | SG&A — period end 2025-06-30 | $1.22B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-06-30.operating_result_k | FMP standardized operating result — period end 2025-06-30 | $1.40B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.revenue_k | Revenue — period end 2024-12-31 | $8.21B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.rd_k | R&D — period end 2024-12-31 | $646.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.sga_k | SG&A — period end 2024-12-31 | $1.18B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2024-12-31.operating_result_k | FMP standardized operating result — period end 2024-12-31 | $2.76B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-17.revenue_actual | Revenue · reported — report date 2026-08-17 | $7.44B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-17.eps_actual | EPS · reported — report date 2026-08-17 | −$1.5600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-10.revenue_actual | Revenue · reported — report date 2026-02-10 | $8.30B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-10.eps_actual | EPS · reported — report date 2026-02-10 | $0.0550 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-02-10.revenue_actual | Revenue · reported — report date 2025-02-10 | $8.21B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-02-10.eps_actual | EPS · reported — report date 2025-02-10 | $0.2594 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-08-13.revenue_actual | Revenue · reported — report date 2024-08-13 | $6.75B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-08-13.eps_actual | EPS · reported — report date 2024-08-13 | $0.1456 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q4 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $1.51B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $2.22B | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $2.22B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $1.30B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$351.65M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$296.51M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-06-30.operating_cash_flow_m | Operating cash flow — period end 2025-06-30 | $2.44B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-06-30.capex_m | Capital expenditure (reported) — period end 2025-06-30 | −$283.23M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2024-12-31.operating_cash_flow_m | Operating cash flow — period end 2024-12-31 | $1.26B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2024-12-31.capex_m | Capital expenditure (reported) — period end 2024-12-31 | −$378.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
own.institutions.depth.ownership_pct | Institutional ownership | 0.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 0.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 6 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 7 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Rhumbline Advisers — shares in provider snapshot | 23,969 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Gamma Investing LLC — shares in provider snapshot | 3,694 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Salomon & Ludwin, LLC — shares in provider snapshot | 1,993 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Pnc Financial Services Group, INC. — shares in provider snapshot | 220 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Ima Wealth, INC. — shares in provider snapshot | 29 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 1 fact from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $16.01 – $36.28 | UNRECORDED | Stored company-profile observation — Captured 2026-10-05 |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.72 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 2 split-adjusted declared dividends with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 2.37% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-06-30.revenue_k,fin.q_table.depth.2025-06-30.rd_k,fin.q_table.depth.2025-06-30.sga_k,fin.q_table.depth.2025-06-30.operating_result_k,fin.q_table.depth.2024-12-31.revenue_k,fin.q_table.depth.2024-12-31.rd_k,fin.q_table.depth.2024-12-31.sga_k,fin.q_table.depth.2024-12-31.operating_result_k. - Earnings-history note. Source series as of 2026-08-17. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-17.revenue_actual,earn.history.depth.2026-08-17.eps_actual,earn.history.depth.2026-02-10.revenue_actual,earn.history.depth.2026-02-10.eps_actual,earn.history.depth.2025-02-10.revenue_actual,earn.history.depth.2025-02-10.eps_actual,earn.history.depth.2024-08-13.revenue_actual,earn.history.depth.2024-08-13.eps_actual. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-06-30.operating_cash_flow_m,fin.opcf.depth.2025-06-30.capex_m,fin.opcf.depth.2024-12-31.operating_cash_flow_m,fin.opcf.depth.2024-12-31.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Business description | CSL Limited is a global biopharmaceutical enterprise dedicated to the research, development, production, marketing, and distribution of a wide array of biopharmaceutical and related healthcare products. The company boasts a significant international presence, with operations spanning major markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China, alongside other territories worldwide. Its business is primarily structured around two key divisions: CSL Behring and Seqirus. The CSL Behring segment specializes in plasma-derived and recombinant therapies, which are crucial for treating serious medical conditions including immunodeficiency, various bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and certain neurological ailments. This division also conducts extensive research into both plasma and non-plasma-based treatments and generates income through licensing agreements and royalties from its proprietary innovations. In contrast, the Seqirus segment is focused on manufacturing and supplying biotherapeutic products that are not derived from plasma, with a particular emphasis on the development of solutions related to influenza. CSL Limited, originally founded in 1916, has its corporate headquarters situated in Parkville, Australia. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Sector / industry (provider taxonomy) | Healthcare / Biotechnology | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Trailing twelve-month ratio set | Quick ratio: 0.97; Current ratio: 2.21; Debt to equity: 0.74; Net margin: -16.1%; Gross margin: 47.8%; Operating margin: 25.6%; Return on assets: -7.5%; Return on equity: -15.1% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Reported versus estimated, last 5 quarters | Captured record · 5 entries
| 2026-08-17 | FMP | Financial Modeling Prep (FMP) earnings |
| Cash, investments and debt | Total debt: $10.90B; Liquidity basis: cash and short-term investments; Total liabilities: $17.34B; Cash and short-term investments: $1.51B; Cash and investments: $1.83B; Long-term investments: $318.00M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $1.83B; Cash and short-term investments: $1.51B; Long-term investments: $318.00M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-06-30; From: 2022-12-31; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $1.51B; Decline: $2.10M; Opening balance: $1.52B; Average change per period: $300,000 Change in cash, cash equivalents and short-term investments between the 2022-12-31 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$9.38B; Total debt: $10.90B; Cash and investments: $1.51B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Distress and quality screens | Altman Z-score: 6.54; Piotroski F-score: 8 Altman Z below 1.8 is the conventional distress zone. For a company holding large cash against negative retained earnings the score mostly reflects the retained-earnings term. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) financial scores |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-12 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Employees | Count: 29,000 | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.